{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:03:36Z","timestamp":1782122616853,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006676","name":"Lilly Deutschland GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.breast.2025.104684","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:13:16Z","timestamp":1766535196000},"page":"104684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Standardized patient coaching improves therapy persistence in patients with hormone receptor\u2013positive, HER2\u2013negative advanced\/metastatic breast cancer treated with abemaciclib"],"prefix":"10.1016","volume":"85","author":[{"given":"Manfred","family":"Welslau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Semmler-Lins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Belleville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Uhrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-Oliver","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benno","family":"Lex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Uleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalija","family":"Deuerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Hesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Langanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2025.104684_bib1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2025.104684_bib2","series-title":"San Antonio Breast Cancer Symposium 2018","article-title":"Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women","year":"2018"},{"key":"10.1016\/j.breast.2025.104684_bib3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061763","article-title":"CDK4\/6 inhibitors-overcoming endocrine resistance is the standard in patients with hormone receptor-positive breast cancer","volume":"15","author":"Nabieva","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2025.104684_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.104684_bib6","series-title":"Overall survival with Abemaciclib in early breast cancer","author":"Johnston","year":"2025"},{"key":"10.1016\/j.breast.2025.104684_bib7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104684_bib8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104684_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.breast.2025.104684_bib10","article-title":"Real-world effectiveness of CDK4\/6i in first-line treatment of HR+\/HER2- advanced\/metastatic breast cancer: updated systematic review","volume":"15","author":"Harbeck","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib11","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis","volume":"20","author":"Giuliano","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/annonc\/mdp039","article-title":"Adherence with adjuvant hormonal therapy for breast cancer","volume":"20","author":"Ruddy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdn646","article-title":"Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer","volume":"20","author":"Ziller","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1200\/JCO.1993.11.6.1189","article-title":"Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring","volume":"11","author":"Waterhouse","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1547-5069.2003.tb00001.x","article-title":"Adherence to long-term therapies: evidence for action","volume":"35","author":"Burkhart","year":"2003","journal-title":"J Nurs Scholarsh"},{"key":"10.1016\/j.breast.2025.104684_bib17","series-title":"Adherence to long-term therapies: evidence for action","author":"Sabat\u00e9","year":"2003"},{"key":"10.1016\/j.breast.2025.104684_bib18","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.2015.63.8619","article-title":"Treatment adherence and its impact on disease-free survival in the Breast International group 1-98 trial of tamoxifen and letrozole, alone and in sequence","volume":"34","author":"Chirgwin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s12885-019-5806-y","article-title":"Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study","volume":"19","author":"Wallwiener","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2025.104684_bib20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1055\/a-1880-0087","article-title":"Implementation of CDK4\/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients - data from the real-world registry PRAEGNANT","volume":"82","author":"Engler","year":"2022","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.breast.2025.104684_bib21","series-title":"San Antonio Breast Cancer Symposium 2022","article-title":"Primary results from the randomized phase II RIGHT choice trial of premenopausal patients with aggressive HR+\/HER2\u2212 advanced breast cancer treated with ribociclib + endocrine therapy vs physician's choice combination chemotherapy","author":"Lu","year":"2022"},{"key":"10.1016\/j.breast.2025.104684_bib22","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-Positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104684_bib23","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"Monarch 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-025-07701-x","article-title":"Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer","volume":"212","author":"Lau","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104684_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.61067","article-title":"Survival following CDK4\/6 inhibitor therapy for hormone receptor-positive, ERBB2-Negative metastatic breast cancer","volume":"8","author":"Berton Giachetti","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2025.104684_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s44276-024-00108-z","article-title":"Overall survival after CDK4\/6 inhibitor dose reduction in women with metastatic breast cancer","volume":"2","author":"Bjerrum","year":"2024","journal-title":"BJC Rep"},{"key":"10.1016\/j.breast.2025.104684_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40360-024-00770-6","article-title":"Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study","volume":"25","author":"Lin","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.breast.2025.104684_bib28","unstructured":"Multinational Association of Supportive Care in Cancer. MASCC Oral Agent Teaching Tool (MOATT\u00a9).."},{"key":"10.1016\/j.breast.2025.104684_bib29","first-page":"583","article-title":"Development of the MASCC teaching tool for patients receiving oral agents for cancer","volume":"18","author":"Kav","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.breast.2025.104684_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1188\/15.ONF.383-389","article-title":"A structured nursing intervention to address oral chemotherapy adherence in patients with non-small cell lung cancer","volume":"42","author":"Boucher","year":"2015","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.breast.2025.104684_bib31","series-title":"Summary OF product characteristics","author":"Lilly","year":"2023"},{"key":"10.1016\/j.breast.2025.104684_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2025.104684_bib33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s13063-023-07306-z","volume":"24","author":"Degenhardt","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.breast.2025.104684_bib34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.annonc.2023.05.003","volume":"34","author":"Harbeck","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib35","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1055\/a-2612-3790","article-title":"Treatment of patients with early breast cancer: 19th St. Gallen international breast cancer consensus discussed against the background of German treatment recommendations","volume":"85","author":"Untch","year":"2025","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.breast.2025.104684_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1025794629878","article-title":"Mammography surveillance following breast cancer","volume":"81","author":"Geller","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104684_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2022.01.012","article-title":"Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review","volume":"62","author":"Yussof","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2025.104684_bib38","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/annonc\/mds653","article-title":"The Patient's Anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer","volume":"24","author":"Hadji","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/annonc\/mdt513","article-title":"COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy","volume":"25","author":"Hadji","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-013-2417-1","article-title":"Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis","volume":"138","author":"Hadji","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104684_bib41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2018.03.020","article-title":"Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: results of the prospective EvAluate-TM study","volume":"96","author":"Nabieva","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2025.104684_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/annonc\/mdx630","article-title":"Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients","volume":"29","author":"Nabieva","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib43","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104684_bib44","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib45","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104684_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114239","article-title":"Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos\/HER2neg breast cancer patients treated with upfront letrozole","volume":"209","author":"Fasching","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2025.104684_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216366","article-title":"The clinical relevance of the NATALEE study: application of the NATALEE criteria to a real-world cohort from two large German breast cancer centers","volume":"24","author":"Schaffler","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625009038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625009038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:10:31Z","timestamp":1770999031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625009038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":48,"alternative-id":["S0960977625009038"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104684","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standardized patient coaching improves therapy persistence in patients with hormone receptor\u2013positive, HER2\u2013negative advanced\/metastatic breast cancer treated with abemaciclib","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104684"}}